Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Shutdown Hangover Hurts Biosimilars, May Benefit Some ANDAs

Executive Summary

As normal operations – and normal budget worries – resume, the agency has some meetings to reschedule.

You may also be interested in...

FDA Shutdown Plans For 2015: Same As 2013, But With More People

'Limited activities related to user fee funded programs' will continue if Congress does not pass a short-term funding measure by Oct. 1.

Shutdown Week Two: Could Sponsors Find A More Focused FDA?

User-fee supported employees continue to work on pending reviews, and the lack of distractions from other tasks may help sponsors as the shutdown continues.

Baxter’s Clinolipid Could Offer Safety Advantages While Mitigating Shortage

Though it doesn’t have a formal labeling claim, olive-oil based parenteral nutrition drug provides marketing advantages compared to soybean fat emulsions drugs, while helping to ease shortage.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts